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High-throughput technologies applied to the analysis of
vaccine responses are likely to reveal the mechanisms
responsible for vaccine-induced protection, aid
understanding of vaccine safety and help accelerate
vaccine development and clinical trials.the mechanism underlying subsequent prevention ofThe need to understand vaccine responses
Vaccines are considered to be one of the most successful
public health interventions in human history, with an
estimated 20 million deaths averted between 2011 and
2020 [1] and significantly improved quality of life
throughout the world. Understanding of the immuno-
logical processes underlying the ‘protection’ conferred by
vaccines has been highly simplified as a result of the lim-
itations of conventional immunological methodologies.
Traditional vaccine development is based on empirical
approaches, which are inherently time-consuming and
costly. However, the recent development of multi-
parameter cellular immunology, high-throughput prote-
omics and the advances in high-resolution genomics and
transcriptomics now provide an opportunity to refine
our understanding of the molecular mechanisms that
underpin vaccine-conferred protection. Such in-depth
knowledge will enable the rational design of vaccine can-
didates, reduce empiricism and lessen the burden of
failed vaccine candidates, thereby expediting the devel-
opment of successful vaccines.
Most vaccines have been designed to induce antibody
(B-cell) responses to kill bacteria and neutralize viruses
and toxins. Although antibodies are the primary* Correspondence: daniel.oconnor@paediatrics.ox.ac.uk
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T-cell immunity (cell-mediated immunity) can also be
detected following administration of routinely adminis-
tered antigens and may be important in protection. For
example, vaccination of individuals latently infected with
varicella-zoster virus (VZV), the shingles vaccine, boosts
VZV-specific T-cell immunity, which is believed to be
viral reactivation.
Assessment of the magnitude of vaccine-specific im-
mune responses (immunogenicity) and their immuno-
logical function is currently undertaken using a variety
of assays (for example, the serum bactericidal assay or
the plaque neutralization assay) and is usually linked to
efficacy to permit licensure. Although standardized and
reproducible, these assays only cover the end result (for
example, antibody titers) of the complex interaction be-
tween a vaccine and the continuum of the innate and
adaptive immune responses. A detailed understanding of
the development of specific, functional and persistent
immunity is missing, and this significantly hampers vac-
cine design.The power of systems biology
Acknowledging this limitation, recent high-throughput
technological advances have revolutionized the way in
which the immune system can be explored after vaccin-
ation and has prompted an increasingly pervasive doctri-
nal shift from reductionist to holistic or ‘systems biology’
research [2]. Systems biology aims to generate in-depth
profiles by integrating multifaceted datasets and harnes-
sing their power to predict, for example, immunogen-
icity following vaccination, using complex computational
approaches. In particular, high-throughput methodolo-
gies for genomic and transcriptomic exploration have
been at the forefront of this technological revolution;
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generation sequencing (NGS).
Microarray technology was instrumental for the devel-
opment of genome-wide association studies (GWASs),
which have identified genetic variants associated with
various human traits, including vaccine immunogenicity
[3]. For example, a variant proximal to HLA-DPB1 has
been associated with responses to hepatitis B vaccine;
intriguingly, this variant has also been associated with
chronicity of hepatitis B infection, suggesting that a gen-
etically determined inability to produce antibodies to
hepatitis B surface antigen predisposes individuals to
chronic hepatitis B infection [4]. Similarly, genetic vari-
ants associated with safety have been explored: variants
in an interferon-stimulated gene (IFI44L) and the mea-
sles receptor (CD46) were found to be associated with
febrile seizures following measles-mumps-rubella vaccin-
ation [5]. Understanding the genetic basis of immuno-
genicity and reactogenicity will reveal the molecular
pathways underlying vaccine outcomes, and this there-
fore highlights the importance of large-scale GWASs in
vaccinology.
Transcriptomic analyses have recently shown signifi-
cant potential for studying responses to various vaccines,
describing early (hours/days) gene signatures following
vaccination that were highly predictive of subsequent
measures of immunogenicity for seasonal influenza [6].
Our ability to accurately predict specific responses is a
core utility of high-throughput methods in vaccine de-
velopment, because early signatures could provide novel
correlates of protection and reveal early mechanisms
that are critical in the development of specific responses.
Recently, NGS approaches have been used to describe
the B-cell receptor repertoire following vaccination; this
could form a new measure of immunogenicity and be
used to identify sequences for the generation of thera-
peutic monoclonal antibodies [7]. Moreover, coupling of
NGS and mass-spectrometry proteomic analyses has
been used to generate data to establish the specific B-
cell repertoire patterns that are associated with serum
IgG responses following tetanus toxoid vaccine [8].
Complementing transcriptomic data, high-resolution
proteomics has provided longitudinal profiles of the pro-
tein expressed following trivalent inactivated influenza
vaccine, a vaccine containing three inactivated influenza
strains [9]. High-dimensional flow cytometry, and more
recently mass cytometry, have been exploited to interro-
gate changes in the cellular compositions before and
after vaccination [10]. Although proteomics and mass
cytometry analyses are less developed than other
methods, these technologies represent an unprecedented
opportunity to understand the complex cellular interplay
underlying the development of antibody and T-cell
responses. The overarching goal of high-throughputmethods is to generate sequential mechanistic under-
standing of the specific immune activation induced by
the different vaccine components (antigen, carrier protein
or adjuvant) that ultimately results in protection. Al-
though characterizing these immunological ‘building
blocks’ is a daunting task, it is clear that high-throughput
technologies have already revolutionized vaccinology re-
search. Taking advantage of these developments is likely
to guide us to targeted stimulation of the immune system
to achieve specific and functional responses.
Implications for clinical trials
Many vaccine candidates never make it past the clinical
trials stages of development. The reasons for this include
safety concerns in early trials, lack of immunogenicity in
human subjects, and finally the significant costs associ-
ated with efficacy trials. Systems biology approaches are
likely to address some of these issues by generating more
detailed knowledge, both to feed into vaccine design and
in early-stage vaccine evaluation. Particularly, under-
standing the molecular biology underlying vaccine re-
sponses is the first step towards targeted vaccine or
adjuvant development to yield optimal immune re-
sponses. Critical to this is the establishment of accurate
sampling frameworks to adequately capture the presence
and amplitude of the molecular events (often short-
lived) that underlie immunological responses. Initially,
this requires frequent sampling and integrative analyses
of multifaceted datasets within hours and days of vaccin-
ation. High-throughput approaches may also provide the
high-resolution depiction of responses to investigational
vaccines needed to identify safety signals in early-phase
vaccine development.
Clinical trials today are designed to measure a small
number of markers in many participants, but high-
throughput methods allow us to measure large numbers
of markers in smaller cohorts. The vast amount of data
collected using these approaches lends itself to modeling
of molecular response signatures (genetic, transcrip-
tional or cell sub-populations) that predict vaccine out-
come, including immunogenicity, reactogenicity and
efficacy. Once such models are sufficiently accurate and
detailed, these data are likely to facilitate accelerated vac-
cine development at reduced cost.
Bridging the gap between new technology and
regulation
Despite the groundbreaking studies published in recent
years, vaccine development and assessment still rely on
measurement of traditional immunological endpoints,
and systems biology has not become integral to most
vaccine trials. Particularly new is the idea of using such
data to support licensing decisions. Collecting large
datasets and validating the use of them in carefully
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vaccines with a known correlate of protection is the key
for validating the use of high-throughput methods for
the assessment of future vaccines. Once specific im-
munological patterns associated with protective vaccin-
ation outcome or markers of safety have been reliably
established, immunological big data may become useful
in supporting vaccine licensing and providing an import-
ant baseline for post-licensing monitoring of safety. Gen-
erating thoroughly validated data in addition to a close
dialog with regulators is pivotal to making these ap-
proaches viable in the regulatory environment.
Access to high-throughput technologies at decreasing
costs now provides the opportunity to unlock the mech-
anisms underlying vaccine-induced protection and gener-
ate critical knowledge to accelerate vaccine development
in preparation for infectious disease threats in the future.
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